A roar­ing Ru­bius sets out to snag $1.8B mar­ket cap in $200M IPO

Af­ter clos­ing two mega-rounds of in­vest­ment with­in eight months of each oth­er, a boom­ing Ru­bius Ther­a­peu­tics has just set terms for a $200 mil­lion IPO.

The Cam­bridge, Mass­a­chu­setts-based com­pa­ny plans to com­mand a $1.8 bil­lion mar­ket cap, of­fer­ing 9.53 mil­lion shares be­tween $20 to $22 each. Ru­bius will list on the Nas­daq un­der the tick­er $RU­BY.

The IPO news comes days af­ter the com­pa­ny an­nounced a new $155 mil­lion project to ren­o­vate a 135,000 square-foot man­u­fac­tur­ing site in Rhode Is­land for its cell ther­a­pies. De­vel­op­ing a new class of med­i­cine calls for a hefty man­u­fac­tur­ing ca­pac­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER